Senate Bill 204, which says an “Opioid treatment program” means a program or practitioner engaged in the treatment of ...

Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

A bill aiming to make opioid treatment programs unlawful was introduced into the West Virginia Senate last week.

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

The FDA has granted Fast Track designation to PP-01 for the mitigation of cannabis withdrawal symptoms in patients with cannabis use disorder.

The 9th "International Symposium on Current Trends in Drug Discovery Research” inaugurated yesterday at CSIR-Central Drug Research Institute, Lucknow. Dr. Radha Rangrajan, Director CSIR-CDRI, Lucknow, ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

PP-01 is an investigational, oral cannabinoid-1 (CB1) partial agonist and GABAergic modulator that targets suppressed CB1 receptors and neurotransmitter dysregulation in the mesolimbic reward pathway.

The prescribing information for Qelbree (viloxazine extended-release capsules) has been updated with new pharmacodynamic and lactation data.